Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Net Cash Flow (2016 - 2025)

Catalyst Pharmaceuticals' Net Cash Flow history spans 16 years, with the latest figure at $19.3 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 74.37% year-over-year to $19.3 million; the TTM value through Dec 2025 reached $191.6 million, down 49.56%, while the annual FY2025 figure was $191.6 million, 49.56% down from the prior year.
  • Net Cash Flow reached $19.3 million in Q4 2025 per CPRX's latest filing, down from $37.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $172.8 million in Q1 2024 to a low of -$150.1 million in Q1 2023.
  • Average Net Cash Flow over 5 years is $28.5 million, with a median of $26.9 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: soared 851.36% in 2021, then plummeted 2267.58% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $16.6 million in 2021, then soared by 154.86% to $42.3 million in 2022, then tumbled by 60.63% to $16.7 million in 2023, then skyrocketed by 351.38% to $75.2 million in 2024, then tumbled by 74.37% to $19.3 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Net Cash Flow are $19.3 million (Q4 2025), $37.1 million (Q3 2025), and $72.1 million (Q2 2025).